Danger of systemic cyclosporine for corneal graft.
OBJECTIVE
To report a case of posttransplant lymphoproliferative disorder (PTLD) in a patient receiving oral cyclosporine (CS) for immunosuppression in a high-risk keratoplasty.


METHODS
A systemic CS therapy was given to prevent graft rejection of a keratoplasty. Risk rejection was high in regard to a previous graft rejection and persistence of a corneal vascularization. One year after the keratoplasty, the patient developed a gastric Epstein-Barr virus (EBV)-induced B cell lymphoma. The outcome was favorable after chemotherapy.


CONCLUSIONS
This unique case of lymphoma (PTLD) in the course of corneal graft management questions the indications and the follow-up of patients with CS therapy and raises the issue of topical CS treatment.
Algros
Marie-Paule
MP
Department of Pathology, Jean Minjoz University Hospital, Boulevard A. Fleming, 25030 Besançon Cedex, France. ana-path@chu-besancon.fr
Angonin
Régis
R
Delbosc
Bernard
B
Cahn
Jean-Yves
JY
Kantelip
Bernadette
B
D000328:Adult; D016572:Cyclosporine / Q000009:adverse effects*; D006084:Graft Rejection / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D015948:Keratoplasty, Penetrating; D016393:Lymphoma, B-Cell / Q000139:chemically induced*; D008297:Male; D013274:Stomach Neoplasms / Q000139:chemically induced*
D007166:Immunosuppressive Agents; D016572:Cyclosporine